small molecule

NUZYRA

OMADACYCLINE TOSYLATE

Loss of exclusivityOctober 2037latest FDA-listed patent expiry

CompanyParatek Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	NUZYRA
Active ingredient	OMADACYCLINE TOSYLATE
Strength	EQ 150MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
10383884	October 2037	use U-2576
10835542	October 2037	use U-2576
10111890	August 2037	use U-2444
9314475	March 2031	product
9265740	October 2030	product
8383610	September 2030	substance
10124014	March 2029	use U-2449
9724358	March 2029	use U-1569

Regulatory exclusivity

Code	Expires
M-320	May 2029
GAIN	October 2028
NCE	October 2023

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Paratek Pharmaceuticals